Dithiothreitol treatment of red blood cells

Publications

Share / Export Citation / Email / Print / Text size:

Immunohematology

American National Red Cross

Subject: Medical Laboratory Technology

GET ALERTS SUBSCRIBE

ISSN: 0894-203X
eISSN: 1930-3955

DESCRIPTION

0
Reader(s)
0
Visit(s)

Comment(s)
0
Share(s)

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue / page

Archive
Volume 33 (2020)
Related articles

VOLUME 33 , ISSUE 4 (Mar 2020) > List of articles

Dithiothreitol treatment of red blood cells

C.B. Bub

Keywords : dithiothreitol (DTT), indirect antiglobulin test, Kell system, daratumumab

Citation Information : Immunohematology. Volume 33, Issue 4, Pages 170-172, DOI: https://doi.org/10.21307/immunohematology-2019-025

License : (CC-BY-NC-ND 4.0)

Published Online: 30-March-2020

ARTICLE

ABSTRACT

Dithiothreitol (DTT), a reducing reagent, has multiple applications in blood bank testing. DTT disrupts the bridging of the disulfide bonds between amino acid residues necessary for structural conformation of some proteins and the bonds holding an IgM molecule in the pentameric formation. DTT treatment of red blood cells (RBCs) can denature or modify certain blood group antigens—in particular, those in the Kell, Lutheran, YT, JMH, LW, Cromer, Indian, Dombrock, and Knops systems—and prevent recognition by the corresponding antibodies. It also destroys RBC CD38, allowing DTT-treated RBCs to be used to avoid testing interference by therapeutic anti-CD38 preparations. DTT treatment can be used to disperse spontaneous agglutination of RBCs caused by heavy IgM autoantibody coating that invalidates ABO/Rh cell grouping and direct antiglobulin tests.

Graphical ABSTRACT

You don't have 'Full Text' access of this article.

Purchase Article Subscribe Journal Share